JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword
- PMID: 32454489
- PMCID: PMC7316660
- DOI: 10.1159/000508750
JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword
Conflict of interest statement
The authors have no conflicts of interest to declare.
Comment in
-
Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.Int Arch Allergy Immunol. 2020;181(8):648-649. doi: 10.1159/000509198. Epub 2020 Jun 12. Int Arch Allergy Immunol. 2020. PMID: 32535597 Free PMC article. No abstract available.
Comment on
-
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.Int Arch Allergy Immunol. 2020;181(6):467-475. doi: 10.1159/000508247. Epub 2020 May 11. Int Arch Allergy Immunol. 2020. PMID: 32392562 Free PMC article. Review.
References
-
- British Society for Hematology Myeloproliferative neoplasms advice. https://b-s-h.org.uk/about-us/news/covid-19-updates/ (accessed 13 May 2020)
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
